Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,221 | 402 | 2,772 |
| Samples | 1,014 | 166 | 830 |
| Peptides | 690 | 119 | 600 |
Function
PIK3CG · Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
Phosphoinositide 3-kinases (PI3Ks) phosphorylate inositol lipids and are involved in the immune response. The protein encoded by this gene is a class I catalytic subunit of PI3K. Like other class I catalytic subunits (p110-alpha p110-beta, and p110-delta), the encoded protein binds a p85 regulatory subunit to form PI3K. This gene is located in a commonly deleted segment of chromosome 7 previously identified in myeloid leukemias. Several transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jun 2015].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 689 amino-acid changes on canonical ENST00000496166 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PIK3CG · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PIK3CG – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 42/612 7% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 50/810 6% |
| Non-Small Cell Lung Carcinoma | 25/304 8% | 69/1390 5% |
| Melanoma | 10/210 5% | 94/1899 5% |
| Colorectal Carcinoma | 21/143 15% | 126/3239 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Neuroendocrine Tumour | 15/154 10% | 11/577 2% |
| Chondrosarcoma | 2/14 14% | 1/75 1% |
| Gastric Carcinoma | 4/74 5% | 55/1809 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 45/1515 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 19/752 3% |
| Head and Neck Carcinoma | 3/85 4% | 35/1574 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Bladder Carcinoma | 1/58 2% | 19/956 2% |
| Glioma | 2/52 4% | 40/2127 2% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Other Sarcomas | 4/69 6% | 9/699 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 42/2550 2% |
| Prostate Carcinoma | 4/13 31% | 29/2105 1% |
| Esophageal Carcinoma | 2/23 9% | 10/769 1% |
| Ovarian Carcinoma | 6/109 6% | 10/998 1% |
| Osteosarcoma | 2/45 4% | 1/166 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Hepatocellular Carcinoma | 1/46 2% | 29/2210 1% |
| Pancreatic Carcinoma | 3/89 3% | 18/1611 1% |
Mutation Distribution
Where PIK3CG is mutated · all tissues, split by cell line vs tissue
How many mutations in PIK3CG were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,221 mutations in PIK3CG
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|